XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Revenue $ 596,415 $ 519,359
ALDURAZYME    
Disaggregation of Revenue [Line Items]    
Revenue 34,403 24,382
Product    
Disaggregation of Revenue [Line Items]    
Revenue 586,426 505,525
Marketed by Company | Total net product revenues marketed by the Company    
Disaggregation of Revenue [Line Items]    
Revenue 552,023 481,143
Marketed by Company | Total net product revenues marketed by the Company | United States    
Disaggregation of Revenue [Line Items]    
Revenue 166,784 150,815
Marketed by Company | Total net product revenues marketed by the Company | Europe    
Disaggregation of Revenue [Line Items]    
Revenue 160,692 156,832
Marketed by Company | Total net product revenues marketed by the Company | Middle East    
Disaggregation of Revenue [Line Items]    
Revenue 91,642 65,607
Marketed by Company | Total net product revenues marketed by the Company | Latin America    
Disaggregation of Revenue [Line Items]    
Revenue 67,748 62,544
Marketed by Company | Total net product revenues marketed by the Company | Rest of world    
Disaggregation of Revenue [Line Items]    
Revenue 65,157 45,345
Marketed by Sanofi | ALDURAZYME    
Disaggregation of Revenue [Line Items]    
Revenue $ 34,403 $ 24,382